» Articles » PMID: 8673132

Mice Lacking the Myotonic Dystrophy Protein Kinase Develop a Late Onset Progressive Myopathy

Overview
Journal Nat Genet
Specialty Genetics
Date 1996 Jul 1
PMID 8673132
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Myotonic dystrophy (DM) is an autosomal dominant disorder resulting from the expansion of a CTG repeat in the 3' untranslated region of a putative protein kinase (DMPK). To elucidate the role of DMPK in DM pathogenesis we have developed Dmpk deficient (Dmpk-/-) mice. Dmpk-/-mice develop a late-onset, progressive skeletal myopathy that shares some pathological features with DM. Muscles from mature mice show variation in fibre size, increased fibre degeneration and fibrosis. Adult Dmpk-/-mice show ultrastructural changes in muscle and a 50% decrease in force generation compared to young mice. Our results indicate that DMPK may be necessary for the maintenance of skeletal muscle structure and function and suggest that a decrease in DMPK levels may contribute to DM pathology.

Citing Articles

Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1.

Hicks S, Frias J, Mishra S, Scotti M, Muscato D, Valero M Mol Ther Nucleic Acids. 2024; 35(4):102338.

PMID: 39391766 PMC: 11465180. DOI: 10.1016/j.omtn.2024.102338.


Promising AAV.U7snRNAs vectors targeting improve DM1 hallmarks in patient-derived cell lines.

Almeida C, Robriquet F, Vetter T, Huang N, Neinast R, Hernandez-Rosario L Front Cell Dev Biol. 2023; 11:1181040.

PMID: 37397246 PMC: 10309041. DOI: 10.3389/fcell.2023.1181040.


Specific -promoter targeting by CRISPRi reverses myotonic dystrophy type 1-associated defects in patient muscle cells.

Porquet F, Weidong L, Jehasse K, Gazon H, Kondili M, Blacher S Mol Ther Nucleic Acids. 2023; 32:857-871.

PMID: 37273786 PMC: 10238591. DOI: 10.1016/j.omtn.2023.05.007.


Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.

De Serres-Berard T, Ait Benichou S, Jauvin D, Boutjdir M, Puymirat J, Chahine M Int J Mol Sci. 2022; 23(21).

PMID: 36362145 PMC: 9657934. DOI: 10.3390/ijms232113359.


Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing.

Izzo M, Battistini J, Provenzano C, Martelli F, Cardinali B, Falcone G Int J Mol Sci. 2022; 23(9).

PMID: 35563013 PMC: 9101876. DOI: 10.3390/ijms23094622.